Professor | Xu Yao Zhang | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Xu Yao Zhang
Contact Information	xuyaozhang@fudan.edu.cn
Language ability	Chinese, English
Province	Shanghai

Upload Avatar (500 x 500)

Name

Xu Yao Zhang

Contact Information

xuyaozhang@fudan.edu.cn

Language ability

Chinese, English

Province

Shanghai

University/Lab Affiliation and Title	Fudan University
Faculty	Pharmaceutical Sciences
Academic Background & Achievements	2015.9 – 2018.7 PhD: Fudan University, School of Pharmacy 2012.9 – 2015.7 Master's: Zhengzhou University, School of Pharmacy 2008.9 – 2012.7 Bachelor's: Zhengzhou University, School of Pharmacy
Work Experience	2020.9 – Present - Fudan University, Department of Biopharmaceuticals - Junior Researcher 2018.7 – 2020.8 - University of Pennsylvania, Tumor Biology - Postdoctoral Researcher
Awards	2021: Selected for Shanghai Youth Science and Technology Talent 'Sailing Plan' 2020: Selected for Shanghai 'Overseas High-Level Talent Introduction Plan' 2018: Outstanding PhD Graduate of Shanghai General Higher Education Institutions 2017: ESMO Immuno Oncology Congress 2017. Poster Discussion & Travel Award 2017: Baosteel Education Scholarship Special Award 2017: JSMO Annual Meeting. Oral Presentation & Travel Award 2016: ESMO Asia 2016 Congress. Poster Presentation & Travel Award 2016: JSMO Annual Meeting. Oral Presentation & Travel Award 2015: Outstanding Graduate of Henan General Higher Education Institutions 2014: National Graduate Scholarship

University/Lab Affiliation and Title

Fudan University

Faculty

Pharmaceutical Sciences

Academic Background & Achievements

2015.9 – 2018.7 PhD: Fudan University, School of Pharmacy
2012.9 – 2015.7 Master's: Zhengzhou University, School of Pharmacy
2008.9 – 2012.7 Bachelor's: Zhengzhou University, School of Pharmacy

Work Experience

2020.9 – Present - Fudan University, Department of Biopharmaceuticals - Junior Researcher
2018.7 – 2020.8 - University of Pennsylvania, Tumor Biology - Postdoctoral Researcher

Awards

2021: Selected for Shanghai Youth Science and Technology Talent 'Sailing Plan'
2020: Selected for Shanghai 'Overseas High-Level Talent Introduction Plan'
2018: Outstanding PhD Graduate of Shanghai General Higher Education Institutions
2017: ESMO Immuno Oncology Congress 2017. Poster Discussion & Travel Award
2017: Baosteel Education Scholarship Special Award
2017: JSMO Annual Meeting. Oral Presentation & Travel Award
2016: ESMO Asia 2016 Congress. Poster Presentation & Travel Award
2016: JSMO Annual Meeting. Oral Presentation & Travel Award
2015: Outstanding Graduate of Henan General Higher Education Institutions
2014: National Graduate Scholarship

Areas of Focus	Development of novel immunotherapy drugs Research on the mechanisms of tumor immunotherapy and microenvironment
Publications	Cell Membrane-Derived Vesicle: A Novel Vehicle for Cancer Immunotherapy, Xu C, Ju D, Zhang X, 2022 Inhibition of PCSK9 enhances the antitumor effect of PD-1 inhibitor in colorectal cancer by promoting the infiltration of CD8+ T cells and the exclusion of Treg cells, Wang R, Liu H, He P, An D, Guo X, Zhang X, Feng M, 2022 Chimeric antigen receptor T cell therapy: challenges and opportunities in lung cancer, Xu C, Ju D, Zhang X, 2022 Eradication of Neuroendocrine Tumors by CDH17CAR T Cells Without Toxicity to Normal Tissue, Feng Z, He X, Zhang X, Wu Y, Xing B, Knowles A, Shan Q, Miller S, Hojnacki T, Ma J, Katona BW, Gade TP, Schrader J, Metz DC, June CH, Hua X, 2022 Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer, Zhang X, Wang Y, Fan J, Chen W, Luan J, Mei X, Wang S, Li Y, Ye L, Li S, Tian W, Yin K, Ju D, 2019 Insights into CD47/SIRPα axis-targeting tumor immunotherapy, Zhang X, Fan J, Ju D, 2018 Disrupting CD47-SIRPα axis alone or combined with autophagy depletion for the therapy of glioblastoma, Zhang X, Chen W, Fan J, Wang S, Xian Z, Luan J, Li Y, Wang Y, Nan Y, Luo M, Li S, Tian W, Ju D, 2018 Inhibition of autophagy potentiated the anti-tumor effects of VEGF and CD47 bispecific therapy in glioblastoma, Zhang X, Wang S, Nan Y, Fan J, Chen W, Luan J, Wang Y, Liang Y, Li S, Tian W, Ju D, 2018 Mesoporous silica nanoparticles induced hepatotoxicity via NLRP3 inflammasome activation and caspase-1-dependent pyroptosis, Zhang X, Luan J, Chen W, Fan J, Nan Y, Wang Y, Liang Y, Meng G, Ju D, 2018 Targeting CD47 and autophagy elicited enhanced anti-tumor effects in non-small cell lung cancer, Zhang X, Fan J, Wang S, Li Y, Wang Y, Li S, Luan J, Wang Z, Song P, Chen Q, Tian W, Ju D, 2017 Synthesis, in vitro and in vivo anticancer activities of novel 4-substituted 1,2-bis(4-chlorophenyl)-pyrazolidine-3,5-dione derivatives, Zhang X, Gu Y, Chen T, Yang D, Wang X, Jiang B, Shao K, Zhao W, Wang C, Wang J, Zhang Q, Liu H*, 2015

Areas of Focus

Development of novel immunotherapy drugs
Research on the mechanisms of tumor immunotherapy and microenvironment

Publications

Cell Membrane-Derived Vesicle: A Novel Vehicle for Cancer Immunotherapy, Xu C, Ju D*, Zhang X*, 2022
Inhibition of PCSK9 enhances the antitumor effect of PD-1 inhibitor in colorectal cancer by promoting the infiltration of CD8+ T cells and the exclusion of Treg cells, Wang R, Liu H, He P, An D, Guo X, Zhang X*, Feng M*, 2022
Chimeric antigen receptor T cell therapy: challenges and opportunities in lung cancer, Xu C, Ju D*, Zhang X*, 2022
Eradication of Neuroendocrine Tumors by CDH17CAR T Cells Without Toxicity to Normal Tissue, Feng Z, He X, Zhang X, Wu Y, Xing B, Knowles A, Shan Q, Miller S, Hojnacki T, Ma J, Katona BW, Gade TP, Schrader J, Metz DC, June CH, Hua X*, 2022
Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer, Zhang X, Wang Y, Fan J, Chen W, Luan J, Mei X, Wang S, Li Y, Ye L, Li S, Tian W, Yin K*, Ju D*, 2019
Insights into CD47/SIRPα axis-targeting tumor immunotherapy, Zhang X, Fan J, Ju D*, 2018
Disrupting CD47-SIRPα axis alone or combined with autophagy depletion for the therapy of glioblastoma, Zhang X, Chen W, Fan J, Wang S, Xian Z, Luan J, Li Y, Wang Y, Nan Y, Luo M, Li S, Tian W, Ju D*, 2018
Inhibition of autophagy potentiated the anti-tumor effects of VEGF and CD47 bispecific therapy in glioblastoma, Zhang X, Wang S, Nan Y, Fan J, Chen W, Luan J, Wang Y, Liang Y, Li S, Tian W, Ju D*, 2018
Mesoporous silica nanoparticles induced hepatotoxicity via NLRP3 inflammasome activation and caspase-1-dependent pyroptosis, Zhang X, Luan J, Chen W, Fan J, Nan Y, Wang Y, Liang Y, Meng G, Ju D*, 2018
Targeting CD47 and autophagy elicited enhanced anti-tumor effects in non-small cell lung cancer, Zhang X, Fan J, Wang S, Li Y, Wang Y, Li S, Luan J, Wang Z, Song P, Chen Q, Tian W, Ju D*, 2017
Synthesis, in vitro and in vivo anticancer activities of novel 4-substituted 1,2-bis(4-chlorophenyl)-pyrazolidine-3,5-dione derivatives, Zhang X, Gu Y, Chen T, Yang D, Wang X, Jiang B, Shao K, Zhao W, Wang C, Wang J, Zhang Q, Liu H*, 2015

Immunotherapy Drug Development Tumor Microenvironment Cancer Therapy Research Mechanisms Novel Drugs Biopharmaceuticals

Lu Wei - Fudan University

Chen Jiang - Fudan University

Dianwen Ju - Fudan University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us